IDEC Inc
Mikio Ishizawa is an experienced marketing and business development professional, currently serving as the Director of Marketing and Business Development at Eliquent Japan, Inc. since July 2020. Prior roles include Commercial Director at Celltrion Healthcare Co., Ltd. and Aegerion Pharmaceuticals, as well as Marketing Director positions at UCB and Merck. Ishizawa began a career at Amgen as an Associate Director in Sales Planning. Educational credentials include a Master's degree in Healthcare Administration from the University of Mississippi and a Bachelor's degree in Pharmaceutical Sciences from Tokyo University of Pharmacy and Life Sciences.
This person is not in any teams
This person is not in any offices
IDEC Inc
IDEC has joined forces with our Validant Group partners to reposition as one global regulatory brand: ELIQUENT Life Sciences. The fusion of five global regulatory consultancies, ELIQUENT Life Sciences is built on the foundation of five global life science consultancies: Validant, Greenleaf Health, DataRevive, Oriel Stat-A-Matrix, and IDEC. ELIQUENT Life Sciences creates an unprecedented assembly of regulatory leaders, industry experts, and technical specialists - brought together to bridge the spectrum of regulatory challenges across the product lifecycle. The collective capabilities of the united ELIQUENT team enable a comprehensive approach that delivers integrated solutions to support pharmaceutical, biotechnology, medical device, and combination product companies navigating the complex regulatory landscape. From thought to finish, concept to commerce, and strategy to execution— ELIQUENT Life Sciences is the singular regulatory resource that clients around the world trust. LEARN MORE about our strategic repositioning and integrated service offerings at eliquent.com Recently, we have created GPTs, “Japan Regulatory Insight,” that allow Q&A about newly issued regulatory notifications in Japan regarding the Japanese Phase 1 waiver and orphan drug designation, which have attracted much attention. If you are a ChatGPT Plus subscriber, please click the link below to use the GPTs "Japan Regulatory Insight." https://chat.openai.com/g/g-D5L83iRSi-japan-regulatory-insight If you would like more detailed advice on your project than GPTs's general advice, please get in touch with IDEC!